Verastem (VSTM) Other Non-Current Assets (2011 - 2026)
Verastem's quarterly Other Non-Current Assets came in at $241000.0 in Q1 2026, little changed year-on-year from $241000.0 in Q1 2025, and down 96.06% quarter-over-quarter from $6.1 million in Q4 2025.
Verastem has reported Other Non-Current Assets for 16 years, with the latest figure at $241000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets changed 0.0% year-over-year to $241000.0; the trailing twelve-month figure through Mar 2026 stood at $241000.0 (changed 0.0% YoY), and the FY2025 full-year result was $6.1 million, up 2436.1% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $241000.0, down from $6.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $6.1 million in Q4 2025, with the low at $58000.0 in Q4 2022.
- Average Other Non-Current Assets over 5 years is $1.7 million, with a median of $241000.0 recorded in 2022.
- Year-over-year, Other Non-Current Assets jumped 7808.62% in 2023 and plunged 94.75% in 2024.
- Tracing VSTM's Other Non-Current Assets over 5 years: stood at $58000.0 in 2022, then jumped by 7808.62% to $4.6 million in 2023, then sank by 94.75% to $241000.0 in 2024, then soared by 2436.1% to $6.1 million in 2025, then sank by 96.06% to $241000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $241000.0 (Q1 2026), $6.1 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Verastem | 425.60 Mn | 243.93 Mn | 15.90 Mn | 241,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 241,000.00 |
| Dec 31, 2025 | 6.11 Mn |
| Sep 30, 2025 | 5.34 Mn |
| Jun 30, 2025 | 5.37 Mn |
| Mar 31, 2025 | 241,000.00 |
| Dec 31, 2024 | 241,000.00 |
| Sep 30, 2024 | 5.05 Mn |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 4.59 Mn |
| Sep 30, 2023 | 241,000.00 |
| Jun 30, 2023 | 241,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 58,000.00 |
| Sep 30, 2022 | 241,000.00 |
| Jun 30, 2022 | 241,000.00 |
| Mar 31, 2022 | 241,000.00 |
| Dec 31, 2021 | 241,000.00 |
| Sep 30, 2021 | 241,000.00 |
| Jun 30, 2021 | 103,000.00 |
| Mar 31, 2021 | 241,000.00 |
| Dec 31, 2020 | 241,000.00 |
| Sep 30, 2020 | 23,000.00 |
| Jun 30, 2020 | 30.62 Mn |
| Mar 31, 2020 | 790,000.00 |
| Dec 31, 2019 | 812,000.00 |
| Sep 30, 2019 | 1.06 Mn |
| Jun 30, 2019 | 1.03 Mn |
| Mar 31, 2019 | 1.03 Mn |
| Dec 31, 2018 | 241,000.00 |
| Sep 30, 2018 | 242,000.00 |
| Jun 30, 2018 | 969,000.00 |
| Mar 31, 2018 | 403,000.00 |
| Dec 31, 2017 | 1.14 Mn |
| Sep 30, 2017 | 162,000.00 |
| Jun 30, 2017 | 162,000.00 |
| Mar 31, 2017 | 162,000.00 |
| Dec 31, 2016 | 162,000.00 |
| Sep 30, 2016 | 162,000.00 |
| Jun 30, 2016 | 162,000.00 |
| Mar 31, 2016 | 162,000.00 |
| Dec 31, 2015 | 203,000.00 |
| Sep 30, 2015 | 203,000.00 |
| Jun 30, 2015 | 293,000.00 |
| Mar 31, 2015 | 282,000.00 |
| Dec 31, 2014 | 203,000.00 |
| Sep 30, 2014 | 319,000.00 |
| Jun 30, 2014 | 203,000.00 |
| Mar 31, 2014 | 330,000.00 |
| Dec 31, 2013 | 331,000.00 |
| Sep 30, 2013 | 322,000.00 |
| Jun 30, 2013 | 295,000.00 |
| Mar 31, 2013 | 86,000.00 |
| Dec 31, 2012 | 86,000.00 |
| Sep 30, 2012 | 86,000.00 |
| Jun 30, 2012 | 86,000.00 |
| Mar 31, 2012 | 86,000.00 |
| Dec 31, 2011 | 1.31 Mn |